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ABSTRACT Innate immune response plays a critical role in controlling invading
pathogens, but such an immune response must be tightly regulated. Insufficient or
overactivated immune responses may lead to harmful or even fatal conse-
quences. To dissect the complex host-parasite interactions and the molecular
mechanisms underlying innate immune responses to infections, here we investi-
gate the role of FOS-like antigen 1 (FOSL1) in regulating the host type I inter-
feron (IFN-I) response to malaria parasite and viral infections. FOSL1 is known as
a component of a transcription factor but was recently implicated in regulating
the IFN-I response to malaria parasite infection. Here we show that FOSL1 can
act as a negative regulator of IFN-I signaling. Upon stimulation with poly(I:C),
malaria parasite-infected red blood cells (iRBCs), or vesicular stomatitis virus
(VSV), FOSL1 “translocated” from the nucleus to the cytoplasm, where it inhib-
ited the interactions between TNF receptor-associated factor 3 (TRAF3), TIR
domain-containing adapter inducing IFN- (TRIF), and Tank-binding kinase 1
(TBK1) via impairing K63-linked polyubiquitination of TRAF3 and TRIF. Impor-
tantly, FOSL1 knockout chimeric mice had lower levels of malaria parasitemia or
VSV titers in peripheral blood and decreased mortality compared with wild-type
(WT) mice. Thus, our findings have identified a new role for FOSL1 in negatively
regulating the host IFN-I response to malaria and viral infections and have iden-
tified a potential drug target for controlling malaria and other diseases.
IMPORTANCE Infections of pathogens can trigger vigorous host immune responses,
including activation and production of type I interferon (IFN-I). In this study, we in-
vestigated the role of FOSL1, a molecule previously known as a transcription factor,
in negatively regulating IFN-I responses to malaria and viral infections. We showed
that FOSL1 was upregulated and translocated into the cytoplasm of cells after stimu-
lation for IFN-I production. FOSL1 could affect TRAF3 and TRIF ubiquitination and
consequently impaired the association of TRAF3, TRIF, and TBK1, leading to inhibi-
tion of IFN-I signaling. In vivo experiments with FOSL1 knockout chimeric mice fur-
ther validated the negative role of FOSL1 in IFN-I production and antimicrobial re-
sponses. This report reveals a new functional role for FOSL1 in IFN-I signaling and
dissects the mechanism by which FOSL1 regulates IFN-I responses to malaria and vi-
ral infections, which can be explored as a potential drug target for disease control
and management.
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Innate immunity serves as the first line of host defense against invading pathogensand relies on the recognition of pathogen-associated molecular patterns (PAMPs)
such as lipopolysaccharide (LPS), DNA, RNA, and carbohydrates from invading patho-
gens by pattern recognition receptors (PRRs) to activate the innate immune response
(1, 2). In recent years, many PRRs have been identified, including retinoic acid-inducible
gene I (RIG-I), melanoma differentiation-associated gene 5 (MDA5), cyclic GMP-AMP
synthase (cGAS), Toll-like receptors (TLRs), and NOD-like receptors (NLRs) (1, 3–8).
Activation of these PRRs recruits various adaptors, such as stimulator of interferon
genes (STING, also known as MPYS, MITA, and Eris), mitochondrial antiviral signaling
protein (MAVS, also called as Cardif, VISA, and IPS-I), and TIR domain-containing adapter
inducing beta interferon (IFN-) (TRIF), to directly interact with TNF receptor-associated
factor 3 (TRAF3) and trigger auto-ubiquitination of TRAF3 (9–12). Ubiquitinated TRAF3
then interacts with Tank-binding kinase 1 (TBK1) to activate the transcription factor
interferon-regulatory factor 3 (IRF3)-mediated type I interferon (IFN-I) signaling and
antipathogen immune responses (13). However, an uncontrolled innate immune re-
sponse can lead to redundant production of IFN-I and proinflammatory cytokines and
cause autoimmune diseases, such as systemic lupus erythematosus (SLE) (14). Thus,
production of IFN-I and other cytokines after pathogen infection needs to be appro-
priately regulated in order to eliminate invading pathogens while avoiding immune
disorders (3, 15).
FOSL1 belongs to a gene family that consists of four members, namely, FOS, FOSB,
FOSL1, and FOSL2, all encoding proteins containing leucine zippers (16). The members
of the FOS transcription factor family are known to differentially regulate trophoblast
migration and invasion (17). FOSL1 is also a member of the activator protein 1 (AP-1)
complex containing Jun (c-jun, junB, junD), Fos (c-fos, fosB, fra-1, fra-2), activating
transcription factor (ATF), and musculoaponeurotic fibrosarcoma (MAF) (16) and con-
tributes to different cellular processes such as proliferation, differentiation, and apo-
ptosis. FOSL1 acts as a key downstream effector of the phosphatidylinositol 3-kinase
(PI3K)/AKT signaling pathway and is responsible for the development of trophoblast
lineages (18), in addition to its role in regulating Mmp9 gene expression (18). Recent
studies showed that histone deacetylases 1, 2, and 3 are recruited to the regulatory and
coding regions of the induced Fosl1 (fra-1) gene (19). Additionally, FOSL1 has been
reported to play a role in various cancers (20). However, these studies mostly focused
on the transcription factor activity of FOSL1 in the nucleus; its function in the cyto-
plasm, especially in regulating the IFN-I response during the host innate immune
response to pathogen infection, remains unknown.
In this report, we show that, after stimulation with poly(I:C) or malaria parasite-
infected red blood cells (iRBCs), FOSL1 was “translocated” from the nucleus to the
cytoplasm, where it interacted with TRAF3 and TRIF to reduce IRF3 phosphorylation and
IFN-I signaling. We further show that FOSL1 negatively regulated IFN-I response by
reducing K63 ubiquitination of TRAF3/TRIF and blocking interaction of TRAF3/TRIF with
TBK1. Our findings identify a previously unrecognized role of FOSL1 in negatively
regulating IFN-I signaling. These molecular interactions can be exploited as potential
targets for the treatment of pathogen infections and, perhaps, autoimmune diseases.
RESULTS
Enhanced IFN-I response in chimeric FOSL1 knockout (KO) mice after malaria
parasite or vesicular stomatitis virus (VSV) infection. From a genome-wide trans-
species expression quantitative trait locus (ts-eQTL) screen, we previously identified a
large number of putative regulators of IFN-I signaling, including FOSL1, which appears
to negatively regulate IFN-I in response to malaria parasite infection (21). To investigate
the functional importance of FOSL1 in regulating innate immune responses in malaria,
we first generated chimeric FOSL1 KO mice by reconstituting irradiated recipient mice
with Fosl1 KO bone marrow cells using CRISPR/Cas9. The Fosl1 gene KO efficiency in the
chimeric mice was verified using Western blot analysis (Fig. 1A). After infection with
Plasmodium N67 parasites, we found that the Fosl1/ chimeric mice had lower
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parasitemia levels and longer host survival times than the control wild-type (WT) mice
(Fig. 1B and C). Significantly larger amounts of IFN- and IFN- were also observed in
the sera of Fosl1/ chimeric mice than in the sera of control mice, particularly at day
1 (h 24) postinfection (Fig. 1D and E). The levels of IFN- and IFN- mRNA in the spleen
of the Fosl1/ chimeric mice were also significantly increased after parasite infection
(see Fig. S1A and B in the supplemental material). With the increased expression of IFN-I
in the spleens of mice infected with N67 parasite or VSV, fosl1 transcript levels were also
increased at day 1 and day 4 postinfection (Fig. S1C and D). The high IFN-I level at day
1 postinfection might contribute to the lower parasitemia at day 5 and the better
survival rate for the Fosl1/ chimeric mice. These results suggest that FOSL1 plays an
important negative role in IFN-I production during malaria.
As a negative regulator of the IFN-I response, FOSL1 may also affect the host
response to viral infections. To test this possibility, we challenged Fosl1/ chimeric
and WT control mice with VSV and found that Fosl1/ chimeric mice were more
resistant to VSV infection than the WT control mice (Fig. 1F). The Fosl1/ chimeric
mice produced significantly higher levels of IFN-I in sera and had lower VSV titers in the
blood than control chimeric mice 24 h after VSV infection (Fig. 1G and H). Taken
together, these results suggest that FOSL1 deficiency enhances the production of IFN-I
and antiviral immunity.
Ectopic expression of FOSL1 suppresses IFN-I response. To further demonstrate
the role of FOSL1 in regulating the IFN-I response, we transfected 293T cells with
increasing amounts (0, 150, and 300 ng) of FOSL1 expression vector, as well as plasmids
containing a luciferase reporter driven by an ISRE (interferon-sensitive response ele-
ment) promoter and renilla luciferase vector as internal control, and then stimulated
the transfected cells with poly(I:C), poly(dAdT), or a green fluorescent protein (GFP)-
tagged VSV (VSV-enhanced GFP [VSV-eGFP]). We found FOSL1 dosage-dependent
inhibition of luciferase signals in all three treatments (Fig. 2A to C). Similar results were
obtained from TLR3-293T cells (293T cells expressing TLR3) and TLR4-293T cells (293T
cells expressing TLR4) after treatments with poly(I:C) and LPS, respectively (Fig. 2D and
E). We also measured IFN- mRNA levels in 293T cells with or without transfection of
plasmid carrying the Fosl1 gene and found significant reduction in IFN- mRNA levels
FIG 1 FOSL1 deficiency increases IFN-I levels and resistance to malaria or vesicular stomatitis virus (VSV) infection. (A) Immunoblot
analysis of FOSL1 knockout efficiency in bone marrow cells of Fosl1/ chimeric mice. IB, immunoblot. (B) Daily parasitemia of wild-type
(WT) and Fosl1/ chimeric mice infected with Plasmodium yoelii nigeriensis N67 (P. y N67). (C) Survival rates of WT mice and Fosl1/
chimeric mice infected with the N67 parasite. (D and E) IFN- (D) and IFN- (E) levels in sera of WT and Fosl1/ chimeric mice at day 1
(D1) and D4 postinfection with the N67 parasite. (F) Survival rates of WT and Fosl1/ chimeric mice intravenously injected with VSV (5 
108 PFU/g). (G) Enzyme-linked immunosorbent assay (ELISA) accessing the level of IFN- production in sera of WT and Fosl1/ chimeric
mice at 0 h and 24 h after VSV infection. (H) The viral titer in the blood at 0 h and 24 h after infection with VSV, assessed using plaque
assay (38). The genetic background of the WT and Fosl1/ chimeric mice (from The Jackson Laboratory) is C57BL/6J, and the protocol
of generation of chimeric mice is described in Materials and Methods. At least five mice were used in each group. *, P  0.05; **, P  0.01;
***, P  0.001; NS, not significantly different from control group (Student’s t test). Data are representative of results of three independent
experiments (means  SD in panels B to H).
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in FOSL1-overexpressing cells at 8 to 12 h after poly(I:C) stimulation (Fig. 2F). These
results suggest that FOSL1 is a negative regulator of IFN-I signaling.
Knockdown of FOSL1 enhances IFN-I production and inhibits viral replication.
To further investigate the role of FOSL1 in suppressing IFN-I response, we used short
hairpin RNA (shRNA) to knock down endogenous FOSL1 in different cell types and then
stimulated them with poly(I:C), poly(dAdT), or VSV-eGFP and measured IFN- mRNA
levels and/or luciferase activities driven by ISRE promoter. Compared with the control
scramble shRNA (scRNA), FOSL1-specific shRNAs greatly reduced FOSL1 protein expres-
sion (Fig. 3A), which led to significantly increased IFN- mRNA levels in 293T cells after
stimulation with poly(I:C) (Fig. 3B). Significantly increased levels of ISRE-driven luciferase
signals were also observed after poly(I:C) or poly(dAdT) treatment or VSV-eGFP infec-
tion (Fig. 3C). Meanwhile, ectopic expression of FOSL1 could restore the inhibition of
ISRE-luc reporter activity induced by poly(I:C) or poly(dAdT) treatment (Fig. 3D and E),
validating the inhibitory activity of FOSL1 in IFN-I signaling. Similarly, we observed
increased IFN- mRNA levels in FOSL1 knockdown RAW264.7 cells compared with
control cells (Fig. 3F and G). The reduction in Fosl1 mRNA levels also led to significant
increase in IFN- mRNA levels (Fig. 3H and I) and reduction of levels of VSV-eGFP-
infected THP-1 cells (Fig. 3J). We also disrupted the Fosl1 gene in splenocytes and
showed that the IFN- mRNA levels were significantly higher than those seen with the
control group after VSV and iRBC stimulations (Fig. S2A and B). Similar results were
observed in trophoblast cells after stimulations with VSV, iRBCs, poly(I:C), and parasite
RNA (Fig. S2C). Taken together, these data demonstrate that FOSL1-specific knockdown
can enhance IFN-I response and antiviral immunity.
FOSL1 acts on molecules upstream of TBK1 and IRF3 in the IFN-I signaling
pathway. Because IRF3 is a transcription factor that plays a critical role in IFN-I
responses to cytosolic RNA/DNA and virus infection (22, 23), we investigated the
expression and phosphorylation of IRF3 with or without overexpression of FOSL1 and
FIG 2 Ectopic expression of FOSL1 inhibits IFN-I signaling. (A to C) Luciferase signals in 293T cells after
transfection with ISRE-luc reporter plasmid together with increasing amounts of FOSL1 overexpression
plasmid (0, 150, and 300 ng), followed by treatment with poly(I:C) (1 g/ml) (A), poly(dAdT) (1 g/ml) (B),
and GFP-tagged VSV (VSV-eGFP) (multiplicity of infection [MOI], 0.01) (C), respectively. (D and E)
Luciferase signals in 293T/TLR3 and 293T/TLR4 cells after transfection with ISRE-luc reporter plasmid
together with increasing amounts of FOSL1 overexpression plasmid, followed by treatment with poly(I:C)
(1 g/ml) (D) or LPS (1 g/ml) (E). (F) Real-time qPCR analysis of IFN- mRNA levels at different time
points after poly(I:C) stimulation with or without overexpression of FOSL1. *, P  0.05; **, P  0.01; ***,
P  0.001; NS, not significantly different from control group (Student’s t test). Data are representative of
results of three independent experiments (means  SD in panels A to F).
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found that FOSL1 could inhibit phosphorylation of IRF3 but not the expression of IRF3
at the total protein level after poly(I:C) stimulation in 293T cells (Fig. 4A). FOSL1
overexpression reduced IRF3 phosphorylation induced by ectopic expression of MAVS
or cGAS plus STING (cGAS/STING) or TRIF, but not that induced by TBK1 (Fig. 4B).
Coexpression of RIG-I, MAVS, and cGAS plus STING with increasing amounts (0, 150, and
300 ng) of FOSL1 in 293T cells significantly reduced ISRE-luc signals, but the same result
was not seen with TRIF, TBK1, IB kinase (IKKi), or IRF3 (Fig. 4C). Similarly, increased
phosphorylation of IRF3 in FOSL1 KO plasmacytoid dendritic cells (pDCs) or trophoblast
cells was observed after stimulation with VSV, poly(I:C), parasite RNA (pRNA), or infected
RBCs (iRBCs) (Fig. 4D and E), leading to increased IFN- mRNA transcript levels in pDCs
FIG 3 Knockdown of FOSL1 enhances IFN-I production and inhibits viral replication. (A) Reduced FOSL1 expression after
shRNA knockdown as detected by Western blotting. (B) IFN- mRNA in WT and FOSL1 knockdown 293T cells stimulated with
poly(I:C) overnight. (C) Luciferase activities in 293T cells transfected with FOSL1-specific shRNAs or control shRNA (scRNA)
together with ISRE luciferase reporter and then stimulated with poly(I:C), poly(dAdT), or GFP-tagged VSV (VSV-eGFP). (D)
Western blot analysis of FOSL1 protein expression in WT, FOSL1 KO, and 293T cells overexpressing FOSL1. (E) ISRE luciferase
signals in WT, FOSL1 KO, or FOSL1 KO 293T cells reconstituted with a plasmid expressing HA-tagged FOSL1 after poly(I:C)
(1 g/ml) or poly(dAdT) (1 g/ml) stimulation overnight. ISRE-luc reporter plasmid was also cotransfected. NT, no treatment.
(F and G) Real-time qPCR analysis of Fosl1 mRNA after shRNA knockdown in RAW264.7 cells (F) and of IFN- mRNA levels after
treatment with poly(I:C) (G). (H and I) The same experiments as described for panels F and G but performed in THP-1 cells. (J)
Flow cytometry assessing the infection of THP-1 cells treated with FOSL1-specific siRNA (FOSL1 siRNA) or scrambled siRNA (Scr
siRNA) and then infected with VSV-eGFP with an MOI of 10. UT, uninfected treatment. *, P  0.05; **, P  0.01; ***, P  0.001;
NS, not significantly different from control group (Student’s t test). Data are representative of results of three independent
experiments (means  SD in panels B, C, and E to J).
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(Fig. 4F) and in trophoblasts (Fig. S2C). These results suggest that FOSL1 acts on
molecules downstream of STING/MAVS/TRIF but upstream of TBK1/IRF3/IKKi in IFN-I
signaling.
To determine whether overexpression of FOSL1 could affect transcriptional levels of
key molecules in IFN-I pathways, we transfected the Fosl1 gene into 293T cells and
found no changes in transcriptional levels of RIG-I, MAVS, TBK1, IRF3, IRF7, TRAF3, or
TRIF with or without poly(I:C) stimulation (Fig. S3A). No change in the total protein level
of these molecules was found after overexpression of FOSL1 either (Fig. S3B). These
results suggest that overexpression of FOSL1 could inhibit IFN-I signaling by affecting
protein interaction or protein modification of signaling molecules but not by changing
mRNA or protein levels of these key genes in the IFN-I pathway.
FOSL1 inhibits IFN-I response by interacting with TRAF3 and TRIF. To identify
the key target molecules of FOSL1, we performed coimmunoprecipitation experiments
and found that FOSL1 physically interacted with TRIF and TRAF3 but not with RIG-I,
MAVS, TBK1, or IRF3 (Fig. 5A). No interaction between FOSL1 and TRAF2, TRAF5, or
TRAF6 was detected (Fig. 5B). Furthermore, we found weak or no endogenous inter-
action of FOSL1 with TRAF3 or TRIF in immune cells (THP-1) without stimulation, but
such interactions were increased after poly(I:C) stimulation (Fig. 5C). TRAF3 is an
important regulator of IFN-I-dependent immune responses. To investigate whether the
regulatory role of FOSL1 in IFN-I signaling is affected by TRAF3, we stimulated WT,
TRAF3 KO, FOSL1 KO, and TRAF3/FOSL1 DKO (double-knockout) bone marrow-derived
macrophages (BMDMs) with poly(I:C) and examined the mRNA expression of IFN- and
ISG56. We found that the upregulation of IFN- and ISG56 in FOSL1 KO BMDMs was
abolished in TRAF3/FOSL1 DKO BMDMs (Fig. 5D), suggesting that TRAF3 is required for
FOSL1 in regulating IFN-I signaling. These results indicate that FOSL1 inhibits the IFN-I
signaling by targeting TRAF3.
FOSL1 inhibits the TRIF/TRAF3/TBK1 complex as well as K63 ubiquitination of
TRAF3 and TRIF. The observations of physical associations of FOSL1 with TRIF and
FIG 4 FOSL1 negatively regulates IFN-I signaling in different cell types. (A) Western blot analysis of phosphorylated IRF3 in
293T cells with or without overexpression of FOSL1 at different time points after poly(I:C) stimulation. (B) Western blot analysis
of phosphorylated IRF3 in whole-cell lysates (WCL) of 293T cells after transfection with plasmids containing indicated genes
encoding various adaptors, with or without overexpression of FOSL1. Vect, vector. (C) Luciferase activities in 293T cells
transfected with ISRE-luc reporter plasmid together with plasmids expressing RIG-I, MAVS, cGAS plus STING, TRIF, TBK1, IKKi,
or IRF3 and increasing amounts (0, 150, and 300 ng) of FOSL1 overexpression plasmid. (D) Western blot analysis of
phosphorylated IRF3 in WT and FOSL1 KO plasmacytoid dendritic cells (pDCs) after stimulation with VSV, poly(I:C), parasite RNA
(pRNA), or infected RBCs (iRBCs) for 16 h. (E) The same experiments as described for panel D but performed in trophoblast cells.
(F) Real-time qPCR analysis of IFN-mRNA levels in WT and FOSL1 KO pDCs stimulated with VSV, poly(I:C), parasite RNA (pRNA),
or infected RBCs (iRBCs) for 16 h. No treatment (NT), control. The FOSL1 KO cells were generated using the LentiCRISPR/Cas9
system as described in Materials and Methods. *, P  0.05; **, P  0.01; ***, P  0.001; NS, not significantly different from
control group (Student’s t test). Data are representative of results of three independent experiments (means  SD in panels
C and F).
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TRAF3 suggest that the inhibitory role of FOSL1 in IFN-I signaling could be mediated by
interrupting the formation of TBK1/TRAF3 and/or TBK1/TRIF complexes. To further
dissect the mechanism of how FOSL1 affects TRIF/TRAF3/TBK1 interaction and IFN-I
signaling, we transfected various combinations of plasmids containing tagged TBK1,
TRIF, TRAF3, or TRAF6 in 293T cells in the presence or absence of FOSL1 and found that
interaction of TBK1 with TRAF3 or TRIF, but not with TRAF6, MAVS, IKKi, or IRF3, was
reduced in the presence of ectopically expressed FOSL1 (Fig. 6A; see also Fig. S4A).
Consistently, knockdown of FOSL1 could enhance the interaction of TBK1 with TRIF and
TRAF3 but not that with TRAF6 (Fig. 6B). These results suggest that FOSL1 specifically
disrupts the formation of the TBK1/TRAF3/TRIF complex.
To determine how FOSL1 inhibits the interaction between TBK1 and TRAF3, we
transfected 293T cells with hemagglutinin (HA)-tagged WT or mutant ubiquitins, along
with FLAG-tagged TRAF3 with or without MYC-tagged FOSL1. Coimmunoprecipitation
and immunoblot analysis showed that K63-linked polyubiquitination of TRAF3 was
decreased in cells overexpressing FOSL1 (Fig. 6C), suggesting that FOSL1 affects
K63-linked ubiquitination of TRAF3. Using a similar strategy, we also showed that FOSL1
inhibited K63 polyubiquitination of TRIF (Fig. S4B). To further confirm the role of FOSL1,
we generated FOSL1 KO macrophages and showed increased K63 ubiquitination, but
not K48-linked ubiquitination, of TRAF3 after VSV stimulation (Fig. 6D). These results
suggest that FOSL1 interacts with TRAF3 and TRIF, leading to reduction of TRAF3 and
TRIF K63 ubiquitination.
FOSL1 expression and cytoplasmic translocation after stimulations. Previous
studies have shown that FOSL1 is dominantly localized in the nucleus (18), which raises
FIG 5 FOSL1 inhibits IFN-I response through modification of signaling molecules upstream of TBK1. (A) Immu-
noassay of 293T cell extracts transfected with plasmids encoding F-RIG-I, F-MAVS, F-TRAF3, F-TBK1, F-IRF3, and
F-TRIF as well as HA-FOSL1, followed by immunoprecipitation (IP) with anti-FLAG beads and immunoblot analysis
with anti-HA antibody. (B) Immunoassay of 293T cell extracts transfected with plasmids encoding F-TRAF2, F-TRAF3,
F-TRAF5, and F-TRAF6 as well as HA-FOSL1, followed by IP with anti-FLAG beads and immunoblot analysis with
anti-HA antibody. (C) IP and immunoblot analysis of THP-1 cell extracts treated with poly(I:C) or medium overnight.
(D) Real-time qPCR analysis of IFN- and ISG56 expression in WT, FOSL1 KO, TRAF3 KO, and FOSL1/TRAF3
double-knockout BMDMs after stimulation with poly(I:C) for 16 h. *, P  0.05; **, P  0.01; ***, P  0.001; NS, not
significantly different from control group (Student’s t test). Data are representative of results of three independent
experiments (means  SD in panel D).
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the issue of how a nuclear protein known to function as a transcription factor could
regulate interactions of TBK1 and TRIF/TRAF3 in IFN-I signaling in the cytoplasm. We
hypothesized that FOSL1 may translocate from the nucleus to the cytoplasm after
stimulation or viral infection, thus regulating the IFN-I pathway. To test this possibility,
we used immunofluorescence microscopy to examine endogenous FOSL1 expression
and localization. We found that FOSL1 was primarily expressed in the nucleus in
unstimulated cells but was translocated to the cytoplasm after poly(I:C) treatment
(Fig. 7A) or incubation with iRBCs (Fig. 7B). To investigate whether the cytoplasmic
translocation of FOSL1 is required for its inhibition in IFN-I signaling pathway, we
generated FOSL1 mutants with amino acid substitutions in the nuclear localization
sequence (NLS) and nuclear export signal (NES) regions according to the prediction of
PSORT (Fig. 7C). We found that FOSL1-NES protein lost the ability to translocate to the
cytoplasm (i.e., remained in the nucleus). In contrast, FOSL1-NLS mutant protein
remained in the cytoplasm with or without stimulation (Fig. 7D). We next generated
FOSL1 KO 293T cells (Fig. S5A) using a CRISPR/Cas9 system and then introduced an
expression vector containing FOSL1-WT, FOSL1-NES, or FOSL1-NLS, along with a plas-
mid containing TRIF, MAVS, or cGAS/STING. We found that both FOSL1-WT and
FOSL1-NLS, but not FOSL1-NES, could inhibit the activity of an ISRE-luc reporter in
FOSL1 KO 293T cells stimulated by TRIF, MAVS, or cGAS/STING overexpression (Fig. 7E).
FIG 6 FOSL1 disrupts TBK1 and TRAF3/TRIF interactions and ubiquitination. (A) Cell lysates from 293T cells were
transfected with expression plasmids for HA-TBK1, F-TRAF3, F-TRAF6, and F-TRIF with or without MYC-FOSL1,
followed by immunoprecipitation (IP) with anti-FLAG and immunoblotting (IB) with antibodies against HA, FLAG,
and MYC. (B) Cell lysates from 293T WT and FOSL1 knockdown cells were transfected with HA-TBK1, F-TRAF3,
F-TRAF6, and F-TRIF, followed by IP with anti-FLAG and IB with antibodies against HA, FLAG, and endogenous
FOSL1. (C) Cell lysates from 293T cells were transfected with expression plasmids for F-TRAF3 and different types
of HA-ubiquitin (HA-UB) with or without overexpression of MYC-FOSL1. Co-IP for TRAF3 was performed using
anti-FLAG breads and IB with antibodies against HA, FLAG, and MYC. (D) Cell lysates from WT and FOSL1 knockout
macrophages (generated by the CRISPR/Cas9 technique) infected with VSV for 18 h (or left uninfected as a control)
were subjected to coimmunoprecipitation using anti-TRAF3 antibody and detected with the indicated antibodies
in Western blotting. Data are representative of three independent experiments with similar results.
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FIG 7 Virus infection induces FOSL1 expression and cytoplasmic translocation leading to inhibition of K63
ubiquitination of TRAF3. (A) Confocal microscopy analysis of FOSL1 in 293T cells with or without poly(I:C)
stimulation; nuclei were detected with DAPI staining (blue). (B) Images of FOSL1 expression in bone marrow-
derived macrophage (BMDM) after incubation with infected red blood cells (iRBCs) for 24 h. (C) A schematic
diagram showing sequences of NLS/NES (nuclear localization signals/nuclear export signals) (predicted at http://
www.psort.org/) of FOSL1 mutants. Amino acid substitutions in the NLS and NES motifs are indicated in red. (D)
Confocal microscopy images of 293T cells transfected with plasmid containing GFP-tagged FOSL1-WT, GFP-tagged
FOSL1-NES, or GFP-tagged FOSL1-NLS, followed by poly(I:C) stimulation or no stimulation (NT) overnight. (E)
Luciferase activity in FOSL1 knockout 293T cells that were transfected with ISRE-luc reporter plasmid together with
expression plasmids for MAVS, TRIF, or cGAS plus STING (cG/ST) as well as FOSL1 WT or mutants as indicated. (F)
Cell lysates from FOSL1 KO 293T cells transfected with plasmids for FLAG-tagged TRAF3 and HA-tagged K63, as well
as MYC-tagged FOSL1 or various MYC-tagged FOSL1 mutants, followed by IP with anti-FLAG and Western blot
analysis with the antibodies as indicated. (G) Confocal microscopy analysis of FOSL1 and TRAF3 in BMDMs with or
without poly(I:C) stimulation. Nuclei were detected with DAPI staining (blue). *, P 0.05; **, P 0.01; ***, P 0.001;
NS, not significantly different from control group (Student’s t test). Data are representative of results of three
independent experiments (means  SD in panel E).
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Additionally, both FOSL1-WT and FOSL1-NLS, but not FOSL1-NES, could reduce TRAF3
K63 ubiquitination (Fig. 7F).
The expression of FOSL1 was also increased in immune cells (THP-1 and peritoneal
macrophages [pMs]) after infection with VSV (Fig. S5B and C). We next determined
whether the cytoplasmic location of FOSL1 is required for its inhibitory function.
Confocal microscope indicated that FOSL1 was translocated to cytoplasm and colocal-
ized with TRAF3 in BMDMs after poly(I:C) stimulation (Fig. 7G). Similarly, we obtained
the nuclear and cytoplasmic fractions, using methods previously described (24), and
investigated endogenous protein interactions between FOSL1 and TRAF3 in the nuclear
and cytoplasmic fractions in the cells with or without VSV stimulation. We found that
FOSL1 was associated with TRAF3 in the cytoplasm, but not in the nuclear fraction, in
macrophages after stimulation (Fig. S5D). Importantly, more K63-linked polyubiquiti-
nated TRAF3 was observed in the cytoplasmic fractions of FOSL1 KO macrophages than
in WT control cells, suggesting that FOSL1 deficiency enhances the K63-linked TRAF3
ubiquitination in the cytoplasm (Fig. S5E). Taken together, these results suggest that
FOSL1 cytoplasmic localization is required for the inhibition of IFN-I signaling.
DISCUSSION
Previous studies showed that FOSL1 is a member of the activator protein 1 (AP-1)
family and is best known as a component of the AP-1 transcription factor complex (16).
FOSL1 is a key downstream effector of the PI3K/AKT signaling pathway that operates by
affecting the expression of genes associated with the invasive-vascular remodeling
trophoblast phenotype and is responsible for the development of trophoblast lineages
integral to establishing the mother-fetus interface (18). In addition, high expression of
FOSL1 caused by rearrangement of the chromosome band at 11q12 appeared to be
associated with desmoplastic fibroblastoma and directly induced MMP-1 and MMP-9
promoter activity in breast cancer progression (16, 20, 25). Recently, results of several
studies have suggested that transcription factors or tumor regulator genes have a
pivotal role in regulating innate immune signaling. For example, the SOX2 transcription
factor has been identified as a bacterium-specific DNA sensor for the activation of TAK1
and TAB2 in neutrophils, which initiate antimicrobial innate immunity (26). The tumor
suppressor protein PTEN controls the phosphorylation site of IRF3, resulting in en-
hanced nucleus translocation of IRF3 and antiviral innate immune signaling (27). The
role of FOSL1 in the host IFN-I response has never been reported. In this report, we
provide compelling evidence for the first time that FOSL1 inhibits IFN-I signaling by
disrupting the interactions among TRAF3, TRIF, and TBK1.
By using a novel genome-wide transspecies expression quantitative trait locus
(ts-eQTL) analysis, we found that FOSL1 was clustered with many genes that function
as negative regulators in IFN-I pathways during malaria parasite infection (21), which
suggest that it may play a role in the host IFN-I response. Our results show that FOSL1
functions as a new negative regulator in the IFN-I signaling pathway and the antiviral
response. Ectopic expression of FOSL1 significantly reduced levels of VSV-induced ISRE
promoter and transcription of IFN-, whereas silencing of FOSL1 had opposite effects
in different cell types. Hence, these results suggest that FOSL1 negatively regulates the
production of IFN-I signaling. We further dissected the details of molecular interactions
and mechanisms of FOSL1 in suppressing IFN-I response. Our data suggest that FOSL1
interacts with TRAF3 and TRIF in immune cells after viral infection. TRAF3, a major
regulator of IFN-I production, serves as a critical link between TLR adaptors and
downstream regulatory kinases (28). We found that FOSL1 interferes with the formation
of TBK1 and the TRIF/TRAF3 complex and reduces K63 ubiquitination of TRAF3, leading
to decreases in IRF3 phosphorylation and IFN-I production.
FOSL1 protein is known as a transcription factor and is normally expressed in the
nucleus. Here we showed that FOSL1 was translocated into the cytoplasm after
poly(I:C), VSV, or iRBC stimulations. Further studies showed that the FOSL1 NES mutant
that lost its ability to translocate to the cytoplasm did not have the activity of inhibiting
the IFN-I signaling pathway. Thus, the K63 ubiquitination of TRAF3 was impaired by
Cai et al. ®
January/February 2017 Volume 8 Issue 1 e02161-16 mbio.asm.org 10
 o
n
 Septem
ber 12, 2018 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
FOSL1 in the cytoplasm. FOSL1 KO chimeric mice had significantly increased IFN- and
IFN- production in the blood and spleen at day 1 and day 4 after malaria parasite
infection, and IFN-I has been associated with inhibition of the growth of blood and liver
stages of malaria parasites (13, 29, 30). Our results suggest that FOSL1 plays a negative
role in IFN-I production and malaria protection. Indeed, FOSL1 KO chimeric mice had
lower parasitemia or VSV titers and longer survival times after malaria parasite or virus
infections. These in vivo studies provide further evidence that FOSL1 plays a critical role
in the regulation of the innate immune response to malaria parasite and viral infection
and reveal a previously uncharacterized function of FOSL1 in inhibiting IFN-I signaling.
On the basis of these results, we propose a working model to illustrate how FOSL1
negatively regulates the IFN-I response (see Fig. S6 in the supplemental material).
Activation of TRIF-, cGAS-STING-, or RIG-I/MDA5-MAVS-mediated IFN-I pathways leads
to production of IFN-I, which triggers a feedback mechanism with “translocation” of
FOSL1 from the nucleus to the cytoplasm, where it inhibits the K63 ubiquitination of
TRAF3 and TRIF and disrupts the formation of TBK1/TRAF3/TRIF complexes. The binding
of FOSL1 to the TBK1 complexes, and the subsequent effects on ubiquitination of TBK1,
results in reduced phosphorylation of IRF3 and suppression of IFN-I production. In
contrast, blockade or disruption of FOSL1 expression or translocation increases IRF3
phosphorylation and IFN-I signaling.
IFN-I plays a pivotal role in host immune responses to various pathogens, including
viral, bacterial, and parasitic infections, but a chronic high level of IFN-I can also lead to
pathological outcomes, including autoimmune diseases such as systemic lupus ery-
thematosus (SLE) (31, 32). Chronic IFN-I signaling has been associated with hyperim-
mune activation and disease progression in persistent viral infections, while IFN-I
blockade before and after establishment of persistent virus infection resulted in en-
hanced virus clearance (33, 34). Similarly, IFN-/ enhances infection through inhibition
of CD4 T cell function during blood-stage infections by Plasmodium berghei and
Plasmodium chabaudi (35). The appropriate level and timing of IFN-I production are
critical for controlling infections without causing pathogenic effects. The discovery of
FOSL1 inhibition of IFN-I responses by interfering with ubiquitination of TRIF and TRAF3
and the interaction of the two molecules with TBK1 could potentially be explored for
developing strategies to modulate host IFN-I responses to infections. Several com-
pounds have been reported to affect FOSL1 expression in different cells. For example,
colon carcinoma cells treated with MEK inhibitor U0126 or PD184352 had lower FOSL1
expression (36). However, these compounds are not specific to FOSL1. New strategies
are needed for identifying novel drugs to regulate FOSL1 expression in the future.
Screening compound libraries for small molecules to block FOSL1 expression in cyto-
plasm or its interaction with TRAF3/TRIF/TBK1 may lead to therapies that can improve
IFN-I response in malaria and other diseases. Interruption of these molecular interac-
tions could be a potential therapeutic strategy for treatment of pathogen infection and,
perhaps, autoimmune diseases.
MATERIALS AND METHODS
Ethics statement. All mouse-related procedures were performed according to experimental proto-
cols approved by the Animal Care and Welfare Committee at The Methodist Hospital Research Institute
(Houston, TX) or according to protocol LMVR11E approved by the Animal Care and Use Committee in
NIAID, National Institutes of Health.
Cell lines, antibodies, and reagents. Human 293T, THP-1, and mouse macrophage RAW 264.7 cell
lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) or RPMI 1640 supplemented with
10% fetal bovine serum (FBS) and 1% antibiotic. Mouse BMDMs were generated by flushing bone marrow
cells from the femurs and tibias of mice and were maintained in DMEM containing 10% FBS and 10%
conditioned media from L929 cells overexpressing macrophage colony-stimulating factor (M-CSF).
Poly(I:C), poly(dAdT), and LPS were from InvivoGen (San Diego, CA). Anti-MAVS (3393), anti-TRIF (4596S),
anti-FOSL1 (5281), anti-TBK1 (3013), and anti-p-IRF3 (4947) were from Cell Signaling Technology, Inc.
(Danvers, MA); Anti-K63 (05-1308) and anti-K48 (05-1307) were from EMD Millipore; anti-IRF3 (sc-9082),
anti-TRAF3 (sc-6933), anti-FOSL1 (SC-605), and anti-GFP (sc-8334) were from Santa Cruz Biotechnology
(Dallas, TX); anti-MYC-horseradish peroxidase (anti-MYC-HRP) (11814150001) was from Roche Applied
Science (Indianapolis, IN); and anti-FLAG-HRP (M2) and anti--actin (A1978) were from Sigma (St. Louis,
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MO). Goat anti-rabbit IgG (HL) Alexa Fluor 488 conjugate antibody (A-11034) was from Thermo Fisher
Scientific. Protein G agarose used for immunoprecipitation was from Santa Cruz Biotechnology.
Knockdown of FOSL1 using RNA interference. FOSL1-specific and control (2-scramble mix) small
interfering RNA (siRNA) oligonucleotides were purchased from Invitrogen and Integrated DNA Technol-
ogies, Inc. (Redwood City, CA). Two human and two mouse FOSL1-specific shRNA plasmids and control
shRNA plasmids were obtained from Open Biosystems (Lafayette, CO). For plasmid transfection, 293T
cells (1.5  105) were plated in 24-well plates and transfected with plasmids using Lipofectamine 2000
(Invitrogen). siRNA was transfected into THP-1 cells using Nucleofector kit V (Invitrogen). Mouse shRNAs
were introduced into BMDMs and RAW cells using lentiviral vectors.
Luciferase activation assays. Cells (1.5  105) from different cell lines were transfected in a 24-well
plate with ISRE firefly luciferase and pRL-TK renilla luciferase plasmids together with other plasmids
containing genes of interest using Lipofectamine 2000. The cells were lysed and measured for luciferase
activity using a dual-luciferase assay kit from Promega (Madison, WI) at the indicated time points after
stimulation with various agents.
Real-time qPCR analysis. Total RNA was isolated from cells using TRIzol reagent (Invitrogen).
First-stand cDNA was prepared from total RNA using a SuperScript III cDNA synthesis kit (Invitrogen).
Real-time quantitative PCR (qPCR) was performed using SYBR green mix and procedures provided by the
manufacturer (Invitrogen).
Western blotting and immunoprecipitation. Whole-cell lysates were separated on 10% SDS-PAGE,
and proteins were transferred to nitrocellulose (NC) membranes for 1.5 h. The membranes were blocked
with blocking buffer containing 5% nonfat milk–phosphate-buffered saline (PBS) at room temperature
(RT) for 1 h before incubation with the primary antibodies at 4°C overnight with gentle shaking. After
three washes performed with washing buffer (for 10 min each time), secondary HRP-conjugated
antibodies were applied to the membranes at RT for 1 h. After the washes, the protein bands were
visualized with chemiluminescent reagents following the manufacturer’s instructions (Millipore, Billerica,
MA). For immunoprecipitation, FLAG- or HA-tagged protein agarose (Santa Cruz Biotechnology) was
added into cell lysates (1:10 [vol/vol]) and incubated at 4°C on a shaker overnight. After four washes, the
beads were eluted using protein loading buffer followed by boiling for 10 min before Western blot
analysis.
Molecular cloning and construction of plasmids. The overexpression entry plasmid for FOSL1
(DQ891054) was obtained from Thermo Fisher Scientific (Waltham, MA) and was subsequently cloned
into pcDNA-HA, pcDNA-FLAG, and pEGFP-C2 vectors. The plasmids containing the deletion domains of
human FOSL1 were generated using PCR with the primers listed in Table S1 in the supplemental material.
Immunofluorescence microscopy. Cells were cultured on coverslips, fixed with 4% (wt/vol) para-
formaldehyde–PBS for 15 min, and then permeabilized with 0.2% (vol/vol) Triton X-100. Primary
antibodies (anti-FOSL1; 5281) were incubated at 4°C overnight after blocking with 3% bovine serum
albumin (BSA)–PBS was performed. After three washes with PBS, the cells were then incubated with
fluorochrome-conjugated secondary antibodies at RT for 1 h. Following three washes, the cells were
stained, sealed with Vectashield antifade mounting medium with DAPI (4=,6-diamidino-2-phenylindole;
Vector Laboratories, Burlingame, CA), and imaged using an Olympus 1X71S1F fluorescence microscope.
Generation of FOSL1 KO mice using CRISPR-Cas9 genome editing. The vector of a CRISPR-Cas9
FOSL1-sgRNA (FOSL1 single-guide RNA) construct and lentiviral particle was prepared according to
methods described previously (37). CRISPR/Cas9 lentiviruses were generated by cotransfection of 293T
cells with lentiviral vectors, pMD2.G, psPAX2, and CRISPR/Cas9-FOSL1-sgRNA or CRISPR/Cas9-V2 as a
control. Bone marrow cells from femurs and tibias of 6-to-8-week-old female C57BL/6 mice were isolated,
transduced with concentrated CRISPR/Cas9 lentiviral vector in the presence of 2 g/ml Polybrene, and
cultured overnight. The cells were harvested and intravenously injected into irradiated (950 cGy)
6-to-8-week-old female C57BL/6 mice. The mice were infected with malaria parasites or VSV 6 to 8 weeks
after reconstitution. The efficiency of gene disruption was monitored using immunoblot analysis of
FOSL1 expression in bone marrow cells of the chimeric mice.
Statistical analysis. Data are represented as means standard deviations (SD) where indicated, and
Student’s t test was used with GraphPad Prism 5.0 software for all statistical analyses. Differences
between groups were considered significant when the P value was 0.05.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/
mBio.02161-16.
Figure S1, TIF file, 0.2 MB.
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Figure S3, TIF file, 0.2 MB.
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